Quantification of gait in mitochondrial m.3243A > G patients: a validation study

Overview of attention for article published in Orphanet Journal of Rare Diseases, May 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#2 of 2,640)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 60 news outlets

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 33 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 81 news stories from 60 outlets.

22 novembre 2017 | Khondrion Presents Phase II KHENERGY Trial Data

Padova News, 22 Nov 2017

– Data supporting Phase III development of KH176 in mitochondrial disease Khondrion, a leading clinical-stage pharmaceutical…

Khondrion stellt die Daten der Phase II der

Direkt Broker , 22 Nov 2017

Nijmegen, Niederlande - Daten befürworten die Phase III der Entwicklung von KH176 für mitochondriale Erkrankungen Khondrion…

News story from Finanz Nachrichten on Wednesday 22 November 2017

Finanz Nachrichten, 22 Nov 2017

Khondrion Presents Phase II KHENERGY Trial Data

BioTech Gate, 22 Nov 2017

/PRNewswire/ -- Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 77 additional news stories.